Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
8.77
-0.02 (-0.23%)
Jun 27, 2025, 4:00 PM - Market closed
Immunome Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Immunome stock ranges from a low of $21 to a high of $33. The average analyst price target of $26.4 forecasts a 201.03% increase in the stock price over the next year.
Price Target: $26.40 (+201.03%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 2, 2025.
Analyst Ratings
The average analyst rating for Immunome stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Lake Street | Lake Street | Strong Buy Initiates $23 | Strong Buy | Initiates | $23 | +162.26% | Apr 2, 2025 |
| Wedbush | Wedbush | Buy Reiterates $33 | Buy | Reiterates | $33 | +276.28% | Mar 20, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $30 | Buy | Reiterates | $30 | +242.08% | Mar 20, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $35 → $25 | Strong Buy | Maintains | $35 → $25 | +185.06% | Mar 20, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $23 → $21 | Buy | Maintains | $23 → $21 | +139.45% | Nov 14, 2024 |
Financial Forecast
Revenue This Year
4.29M
from 9.04M
Decreased by -52.52%
Revenue Next Year
17.63M
from 4.29M
Increased by 310.65%
EPS This Year
-2.26
from -5.00
EPS Next Year
-2.46
from -2.26
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 9.5M | 54.6M | 161.2M | ||
| Avg | 4.3M | 17.6M | 73.4M | ||
| Low | n/a | n/a | 34.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.5% | 1,171.8% | 814.3% | ||
| Avg | -52.5% | 310.6% | 316.3% | ||
| Low | - | - | 96.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.93 | -1.82 | -1.34 | ||
| Avg | -2.26 | -2.46 | -2.28 | ||
| Low | -2.56 | -2.87 | -3.28 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.